Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) has received an average recommendation of “Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $26.33.

A number of analysts recently issued reports on CRBP shares. Noble Financial increased their target price on shares of Corbus Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Raymond James Financial started coverage on shares of Corbus Pharmaceuticals in a research report on Friday. They set an “outperform” rating and a $24.00 target price for the company. BidaskClub raised shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the company an “overweight” rating in a research report on Thursday, December 14th.

Corbus Pharmaceuticals (NASDAQ:CRBP) traded up $0.55 on Friday, reaching $8.80. 1,249,804 shares of the company were exchanged, compared to its average volume of 790,123. The firm has a market cap of $482.88, a P/E ratio of -14.19 and a beta of 174.68. Corbus Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $10.50.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.02. The firm had revenue of $0.80 million during the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. equities analysts predict that Corbus Pharmaceuticals will post -0.6 earnings per share for the current fiscal year.

In other news, Director David P. Hochman acquired 10,000 shares of the stock in a transaction on Friday, November 10th. The stock was bought at an average price of $7.08 per share, with a total value of $70,800.00. Following the completion of the transaction, the director now directly owns 459,500 shares of the company’s stock, valued at $3,253,260. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David P. Hochman acquired 5,000 shares of the stock in a transaction on Monday, November 13th. The stock was purchased at an average cost of $6.90 per share, with a total value of $34,500.00. The disclosure for this purchase can be found here. Insiders acquired 25,336 shares of company stock valued at $175,632 in the last ninety days. 11.90% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Corbus Pharmaceuticals by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock valued at $9,850,000 after buying an additional 307,979 shares during the last quarter. State Street Corp boosted its stake in shares of Corbus Pharmaceuticals by 2,998.2% during the 2nd quarter. State Street Corp now owns 588,662 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 569,662 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Corbus Pharmaceuticals by 814.3% during the 2nd quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock valued at $3,039,000 after buying an additional 429,584 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Corbus Pharmaceuticals by 4.3% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 444,504 shares of the biopharmaceutical company’s stock valued at $3,178,000 after buying an additional 18,224 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Corbus Pharmaceuticals by 9.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 150,135 shares of the biopharmaceutical company’s stock valued at $1,073,000 after buying an additional 13,323 shares during the last quarter. 27.50% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Analysts Set Corbus Pharmaceuticals Holdings Inc (CRBP) PT at $26.33” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/01/22/analysts-set-corbus-pharmaceuticals-holdings-inc-crbp-pt-at-26-33.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.